Immediate and long-term consequences of COVID-19 infections for the development of neurological disease.
Cognition
Cytokine
Decline
NLRP3 inflammasome
Neurodegeneration
Neuroinflammation
Systemic inflammation
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
04 06 2020
04 06 2020
Historique:
received:
06
05
2020
accepted:
27
05
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. While these symptoms arise acutely during the course of infection, less is known about the possible long-term consequences for the brain. Severely affected COVID-19 cases experience high levels of proinflammatory cytokines and acute respiratory dysfunction and often require assisted ventilation. All these factors have been suggested to cause cognitive decline. Pathogenetically, this may result from direct negative effects of the immune reaction, acceleration or aggravation of pre-existing cognitive deficits, or de novo induction of a neurodegenerative disease. This article summarizes the current understanding of neurological symptoms of COVID-19 and hypothesizes that affected patients may be at higher risk of developing cognitive decline after overcoming the primary COVID-19 infection. A structured prospective evaluation should analyze the likelihood, time course, and severity of cognitive impairment following the COVID-19 pandemic.
Identifiants
pubmed: 32498691
doi: 10.1186/s13195-020-00640-3
pii: 10.1186/s13195-020-00640-3
pmc: PMC7271826
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Subventions
Organisme : NIA NIH HHS
ID : R01 AG059752
Pays : United States
Références
Nature. 2019 Nov;575(7784):669-673
pubmed: 31748742
EMBO J. 2019 Sep 2;38(17):e101064
pubmed: 31359456
Nature. 2013 Jan 31;493(7434):674-8
pubmed: 23254930
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
Nature. 2017 Dec 20;552(7685):355-361
pubmed: 29293211
Lancet Respir Med. 2018 Mar;6(3):213-222
pubmed: 29508705
N Engl J Med. 2020 Apr 17;:
pubmed: 32302082
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am J Respir Cell Mol Biol. 2014 Feb;50(2):270-80
pubmed: 24007300
J Neuroradiol. 2020 May 4;:
pubmed: 32389423
FASEB J. 2019 Aug;33(8):8865-8877
pubmed: 31034780
Lancet Neurol. 2014 Jun;13(6):630-6
pubmed: 24849863
Crit Care. 2019 Nov 12;23(1):352
pubmed: 31718695
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
JAMA. 2010 Oct 27;304(16):1787-94
pubmed: 20978258
Eur J Neurol. 2020 Apr 30;:
pubmed: 32352618
Cell Death Dis. 2017 Nov 16;8(11):e3170
pubmed: 29144508
Neurology. 2020 Apr 17;:
pubmed: 32303650
J Neurol Neurosurg Psychiatry. 2020 Apr 30;:
pubmed: 32354768
Eur Arch Otorhinolaryngol. 2020 Apr 6;:
pubmed: 32253535
Travel Med Infect Dis. 2020 Mar 24;:101642
pubmed: 32220634
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Neuroinflammation. 2018 Jan 05;15(1):4
pubmed: 29304864
JAMA Neurol. 2020 Apr 10;:
pubmed: 32275288
Eur J Neurol. 2015 Feb;22(2):410-5
pubmed: 24724819
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504